US PRE-MARKET MOVERS: REGN, F, D, RAMP, UNH, BIO, NOW

Newsquawk ·

ES -0.2% NQ -0.1% RTY -0.1% REGN -11.5%: Melanoma combo fails Phase 3 primary endpoint.. F +5.5%: Plans to launch seven new vehicle models in Europe by 2029. D +15.0%, NEE -1.7%: NEE to acquire D in all-stock deal. RAMP +27.8%: Publicis agreed to buy RAMP in an all-cash $2.2B deal. UNH -3.8%: BRK.B exits UNH position. BIO +7.5%: Elliott builds BIO stake. NOW +5.1%: BofA reinstated coverage with a 'Buy' rating and $130 PT.

AI 시장 분석

In US premarket trading major indices were slightly lower while individual stocks showed large volatility. REGN plunged -11.5% after a Phase 3 failure for a melanoma combination therapy, sending a negative signal to the biotech/oncology sector. F announced plans to launch seven new models in Europe through 2029, positive for the automotive and parts/battery demand. D jumped +15.0% on news of an all-stock acquisition by NEE, but NEE fell -1.7% amid dilution and regulatory concerns. Publicis's $2.2B cash acquisition of RAMP, BRK.B's liquidation of its UNH stake, Elliott increasing its BIO position, and BofA resuming coverage of NOW signal sectoral buy/sell reallocation and an expansion of M&A, activist, and analyst influence.

상승 영향

하락 영향

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 50% · Bearish (Short) 50%

488 participants

Related News

원문 보기 — Newsquawk